Davunetide vs Pinealon

Stabilizes microtubules by interacting with tubulin and microtubule-associated proteins. Activates SIRT1, reduces amyloid-β toxicity, and enhances synaptic plasticity. Protects against tau hyperphosphorylation.

Davunetide (AL-108; NAP; NAPVSIPQ) is a synthetic octapeptide derived from activity-dependent neuroprotective protein (ADNP), initially identified as a neuroprotective sequence from ADNP and investigated in clinical trials as a candidate treatment for cognitive impairment associated with schizophrenia and tauopathies including progressive supranuclear palsy. Davunetide is proposed to stabilize microtubule dynamics by interacting with tubulin and preventing tau hyperphosphorylation-related cytoskeletal disruption, and preclinical models demonstrated neuroprotective and procognitive effects at nanomolar concentrations. Clinical investigation included Phase 2 trials examining cognitive outcomes and MRS neuroimaging biomarkers in schizophrenia patients, and a Phase 2/3 trial in progressive supranuclear palsy; results showed some neurochemical effects but no consistent meaningful cognitive improvement across clinical endpoints, and the PSP program did not meet its primary outcomes. Davunetide has no FDA approval and no approved indication in any jurisdiction; clinical development has been discontinued following negative trial outcomes, and while its preclinical neuroprotective profile remains scientifically interesting, the clinical evidence does not establish efficacy for cognitive enhancement or neuroprotection in any condition.

Glu-Asp-Arg tripeptide; penetrates blood-brain barrier; modulates gene expression in neurons; reduces oxidative stress in brain tissue

Pinealon is a synthetic tripeptide (Glu-Asp-Arg, EDR) classified as a Khavinson-class bioregulator peptide targeted at the pineal gland and central nervous system, investigated for neuroprotective and anti-aging properties in brain tissue. Like other short bioregulator peptides in the Khavinson series, pinealon is proposed to reach neuronal target cells via amino acid transporter mechanisms and modulate gene expression in aging neurons, with suggested effects on mitochondrial function and neuronal structural integrity. Published research on related Khavinson tripeptides has demonstrated restoration of neuronal spine density in in vitro models of Alzheimer's disease and modulation of epigenetic targets in aging neural tissue. Pinealon has not received FDA approval; evidence derives from Russian-origin preclinical studies and Khavinson-class literature, with no independent clinical trials published in Western indexed journals. Pinealon research interest centers on its role as a pineal gland bioregulator with neuroprotective and sleep-regulatory properties. As a pineal-derived peptide, pinealon is investigated for its potential to support melatonin pathway regulation, circadian rhythm maintenance, and age-related cognitive decline — areas where pineal gland function plays a central role. Research in aged animal models has examined pinealon-class peptides for effects on neuronal integrity, oxidative stress markers in brain tissue, and the preservation of sleep architecture with aging. The pineal gland produces melatonin and regulates circadian biology; as a targeted bioregulator for this tissue, pinealon represents an approach to age-associated disruptions in sleep quality and neuroendocrine signaling that is mechanistically distinct from melatonin supplementation itself. Pinealon as a peptide for sleep: Research interest in pinealon for sleep support derives from its classification as a pineal gland bioregulator. Unlike melatonin, which directly supplements a sleep hormone, pinealon is proposed to work upstream by supporting the regulatory function of the pineal gland itself — potentially offering a more targeted approach to age-related sleep disruption in a research context. This mechanism distinguishes pinealon from direct sedative or melatonin-based sleep interventions. Pinealon is a research compound; no clinical trials have established safety or efficacy for any indication including sleep support.